Cassidy Bio

Operating from Tel Aviv, Israel, Cassidy Bio is a biotechnology firm positioning itself at the intersection of artificial intelligence and genetic medicine. The company is developing a sophisticated platform to accelerate the creation of gene-editing therapeutics, with a core focus on CRISPR-based technologies. Its business model centers on providing bespoke solutions to research and development partners, enabling them to de-risk and fast-track the therapeutic development lifecycle. Cassidy Bio leverages a combination of cutting-edge AI, including large language models (LLMs), and advanced wet lab capabilities to optimize and validate its findings. The company was established in March 2024 and operates within the health tech and life sciences sector.

In July 2025, Cassidy Bio announced the successful closure of an $8 million seed funding round, a significant event intended to propel its preclinical research and the development of its next-generation therapeutic platforms. This capital injection is earmarked for enhancing laboratory facilities and expanding its scientific team. The financing was supported by a syndicate of investors including 10D, Ahren Innovation Capital, AION Labs, Amiti Ventures, and Israel Biotech Fund. Prior to this, the company was part of an accelerator/incubator program with AION Labs.

The company's primary offering is a predictive platform designed for the intricate process of guide RNA (gRNA) design, which is critical for the precision of CRISPR systems. This AI-driven tool provides rapid gRNA ranking and comprehensive on/off-target predictions across various editing technologies and cell types. By identifying potential genotoxicity and other risks early on, the platform aims to reduce adverse outcomes in clinical applications and streamline decision-making for its partners. The company's leadership includes Dr. Ayal Hendel, a recognized expert in genome editing and gene therapy from Bar-Ilan University with postdoctoral training at Stanford University, and Dr. Yaron Shmueli, who brings over 25 years of experience in AI and machine learning, including roles at Meta Platforms.

Keywords: gene editing, CRISPR, guide RNA, gRNA design, artificial intelligence in biotech, large language models in biology, therapeutic development, preclinical research, biotechnology, life sciences, genetic medicine, predictive platform, genomic data, Tel Aviv, AION Labs, computational biology, drug discovery, precision medicine, genomic variants, off-target effects